Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Barcelona
Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 43 Madrid 37 Valencia 20 Seville 12 L'Hospitalet de Llobregat 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Merck Sharp & Dohme LLC113 Novartis Pharmaceuticals111 Janssen Research & Development, LLC96 Hoffmann-La Roche85 Clear sponsor filter
Site location
Barcelona43 Madrid37 Valencia20 Seville12 L'Hospitalet de Llobregat10
All 47 locations
Target enrolment
to

Trials with a site in Barcelona

43 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Boehringer Ingelheim
Phase 3
270
Barcelona, Madrid, Málaga, Valencia
2026-11-09
Not yet open
Boehringer Ingelheim
Phase 1
90
Barcelona, Valencia
2026-10-26
Not yet open
Boehringer Ingelheim
Phase 1/2
55
Barcelona, Madrid, Valencia
2026-10-05
Recruiting
Boehringer Ingelheim
Phase 1
137
Barcelona, Madrid, Navarra, Valencia
2026-09-21
Recruiting
Boehringer Ingelheim
Phase 3
466
Badalona, Barcelona, Córdoba, Galdakao, Granollers, Hospitalet Llobregat, L'Hospitalet de Llobregat, Madrid
2026-09-17
Recruiting
Boehringer Ingelheim
Phase 3
448
Badalona, Barakaldo, Barcelona, Huelva, L'Hospitalet Del Llobregat, Madrid, Sabadell, Valencia
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
35
Barcelona, Seville
2026-07-21
Recruiting
Boehringer Ingelheim
Phase 3
390
Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia
2026-07-10
Recruiting
Boehringer Ingelheim
Phase 2
60
Barcelona, Madrid, Seville
2026-06-04
Recruiting
Boehringer Ingelheim
Phase 1
60
Barcelona, Pamplona, Valencia
2026-05-01
Recruiting
Boehringer Ingelheim
Phase 2
405
Badalona, Barcelona, Galdakao, Madrid, Vitoria-Gasteiz
2026-04-20
Recruiting
Boehringer Ingelheim
Phase 2
132
Barcelona, Esplugues de Llobregat, Granada, Madrid, Valencia
2026-03-23
Recruiting
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim
Phase 1
187
Barcelona, Madrid
2026-02-27
Recruiting
Boehringer Ingelheim
Phase 3
1,325
A Coruña, Alicante, Barakaldo, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Almería, Barcelona, Granada, Madrid
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Barcelona, Burgos, Elche, Jerez de la Frontera, Madrid, Majadahonda, Málaga, Pamplona
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
120
Barcelona, Bilbao, Málaga, Seville
2025-12-09
Active, closed
Boehringer Ingelheim
Phase 2
81
Barcelona, L Hospitalet Del Llobregat, Madrid, Seville
2025-11-13
Recruiting
Boehringer Ingelheim
Phase 3
670
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca
2025-11-07
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville
2025-09-13
Active, closed
Boehringer Ingelheim
Phase 1
16
Barcelona, Madrid, Seville
2025-07-29
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Badalona, Barcelona, Beiro, Córdoba, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
1,755
A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat
2025-06-09
Active, closed
Boehringer Ingelheim
Phase 1/2
5
Barcelona
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Barcelona, Madrid, Sanlúcar de Barrameda, Torrejón de Ardoz, Valencia, Villamartín
2025-05-20
Active, closed
Boehringer Ingelheim
Phase 1
91
Barcelona
2025-05-14
Recruiting
Boehringer Ingelheim
Phase 3
1,590
A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago de Compostela
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,800
A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia
2024-10-11
Recruiting
Boehringer Ingelheim
Phase 1/2
768
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela
2024-06-17
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid
2024-05-06
Active, closed
Boehringer Ingelheim
Phase 3
428
A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia
2024-02-09
Recruiting
Boehringer Ingelheim
Phase 1
20
Barcelona, Madrid
2024-01-30
Active, closed
Boehringer Ingelheim
Phase 1
65
Barcelona, Madrid
2024-01-22
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Barcelona, Madrid, Málaga, Valencia
2023-10-13
Active, closed
Boehringer Ingelheim
Phase 2
268
Barcelona, L'Hospitalet de Llobregat, Mérida, Pozuelo de Alarcón
2023-09-08
Active, closed
Boehringer Ingelheim
Phase 1
59
Barcelona, Córdoba, Madrid
2023-05-11
Recruiting
Boehringer Ingelheim
Phase 1
66
Barcelona, Madrid, Valencia
2023-02-24
Active, closed
Boehringer Ingelheim
Phase 1
151
Badalona, Barcelona, Madrid, Pamplona
2021-10-18
Active, closed
Boehringer Ingelheim
Phase 1
30
Barcelona
2021-09-09
Active, closed
Boehringer Ingelheim
Phase 1
554
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
2021-07-02
Active, closed
Boehringer Ingelheim
Phase 1
306
Barcelona, Pamplona, Valencia
2020-07-29
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Barcelona that also match the filters currently applied.

How many clinical trials are recruiting in Barcelona?

26 of the 43 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barcelona), 43 studies
PhaseStudiesRecruitingShare
Phase 3191544.2%
Phase 114532.6%
Phase 27516.3%
Phase 1/2317%

Most active sponsors

Lead sponsors with the most studies (Barcelona)
Lead sponsorStudiesRecruiting
Boehringer Ingelheim4326
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.